Therefore, positron emission tomography (PET) imaging with the synthetic GRPr antagonist [68Ga]Ga-RM2 has emerged as a useful tool for biopsy guidance in patients with suspected PCa [12] and for staging and localization of disease in patients with primary PCa and patients with biochemical recurrence (BCR) and negative findings on conventional imaging and evaluation of treatment response [8,13,14,15,16]. The gene discussed is GRPR; the disease is posterior cortical atrophy.